MRNA

N/A

Moderna, Inc.

Healthcare · Rank #497 · Analyzed Oct 18, 2026

$218.01

Current Price

⚠️ Unverified — fails data-quality checks

This ticker did not clear our Definition of Done, so its valuation is shown for transparency but should not be trusted:

• Insufficient data to rate
• <2 valuation methods computed

$17.14

Intrinsic Value

-92.1%

Upside/Downside

0/10

Score

1.2/5

Quality

Analysis Summary

Valuation Consensus0/1 methods agree

Quality Score1.2/5.0

Framework RatingINSUFFICIENT DATA

Price vs Intrinsic ValueOvervalued by 92.1%

Fair Value Range

Low$17.14

Base (IV)$17.14

High$17.14

Entry Points

Conservative$12.00

Moderate$17.14

Aggressive$12.00

⚠️ Warnings

Biotech/pharma: negative margins from R&D — using forward estimates
Insufficient data: fewer than 2 valuation methods

Quality & Moat Breakdown

Return on Equity-39.0% → 0/1.0

Debt LevelD/E 19 → 1.0/1.0

Revenue QualityGrowth -40.7%, margin Δ+2.9% → 0/1.0

Moat Strength0.0/5 → 0/1.0

Profit Margins-141.4% → 0.25/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.